Experimental CAR t therapy targets tough childhood leukemia
NCT ID NCT06609928
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new type of immune cell therapy called FOLR1 CAR T cells for children aged 6 and under with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy involves taking a child's own immune cells, modifying them in the lab to recognize and attack leukemia cells, and infusing them back. The main goals are to see if the treatment is safe and to find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FOLR1 CAR T cells (a type of immune cell therapy)
What this could lead to
If it works, this could point toward a new treatment option for children with hard-to-treat AML that has returned or not responded to standard therapy.
What could go wrong
This is a very early phase 1 trial with only 12 children, so it is primarily testing safety and dosing. The therapy may not work, and there are risks of serious side effects like low blood counts and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact